Type I interferons (IFNs) inhibit angiogenesis, the sprouting of new blood vessels, during tissue development, remodeling, and tumor growth. One of the major targets type I IFNs inhibit are circulating monocytes, which promote vascular development by secreting growth factors, chemokines, and proteases. This study tested the hypothesis that IFN-β directly inhibits monocyte chemotaxis towards VEGF. We were interested in looking at chemotaxis towards VEGF because VEGF is known to create a pro-angiogenesis environment by acting as a stimulator and chemotactic factor for endothelial cells and monocytes. Here, we demonstrate that IFN-β, a type I IFN, downregulates neuropilin-1 (NRP-1) expression by human monocytes and inhibits chemotaxis induced by vascular endothelial growth factor (VEGF), a NRP-1 ligand. Together, the data suggest that IFN-β directly downregulates NRP-1 expression in monocytes, thus inhibiting monocyte chemotaxis toward a VEGF enriched environment.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8119361 | PMC |
| http://dx.doi.org/10.1016/j.cyto.2021.155519 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pitavastatin, Procollagen Pathways, and Plaque Stabilization in Patients With HIV: A Secondary Analysis of the REPRIEVE Randomized Clinical Trial.
JAMA Cardiol
December 2024
Metabolism Unit, Massachusetts General Hospital, Harvard Medical School, Boston.
Article Synopsis
Neuropilin-1 as a Key Molecule for Renal Recovery in Lupus Nephritis: Insights from an NZB/W F1 Mouse Model.
Int J Mol Sci
October 2024
Rheumatology Research Group-Lupus Unit, Vall d'Hebrón University Hospital, Vall d'Hebrón Research Institute (VHIR), Universitat Autònoma de Barcelona (UAB), 08193 Barcelona, Spain.
Article Synopsis
- - Systemic lupus erythematosus (SLE) is an autoimmune disease affecting many organs, with lupus nephritis (LN) impacting 40-50% of patients and potentially leading to serious kidney complications like end-stage renal disease (ESRD).
- - This study investigates the role of neuropilin-1 (NRP-1), a receptor in kidney tissue, as a biomarker for kidney recovery in LN using a mouse model, demonstrating a significant increase in NRP-1 levels over time.
- - High urinary NRP-1 levels (above 34.40 ng/mL) were strongly associated with positive renal outcomes, highlighting NRP-1's potential as a reliable biomarker for kidney recovery in
Conventional DMARDs therapy decreases disease activity and inflammation in newly diagnosed patients with rheumatoid arthritis by increasing FoxP3, Sema-3A, and Nrp-1 gene expression.
Inflammopharmacology
December 2024
Clinical Research Development Center, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Article Synopsis
- - The study explores the levels of interleukin-6 (IL-6) and interleukin-10 (IL-10), along with the expression of various genes associated with immune regulation, in newly diagnosed rheumatoid arthritis (RA) patients before and after treatment with DMARDs compared to healthy individuals.
- - Results indicated that RA patients had significantly higher IL-6 levels and lower IL-10 levels before treatment, but IL-6 decreased and IL-10 increased post-treatment with DMARDs, showing an improvement in their inflammatory profiles.
- - Gene expression analysis showed that certain regulatory genes (FoxP3, Sema-3A, Nrp-1) were upregulated after treatment, indicating a beneficial effect
Assessment of Clinical Analgesic Levels and Serum Biomarkers in Patients with Rheumatoid Arthritis: A Randomized Controlled Trial Comparing the Efficacy of Diclofenac and Methotrexate Combined Therapy with Extracorporeal Shockwave Therapy.
Pain Res Manag
August 2024
School of Pharmacy and State Key Laboratory for the Quality Research of Chinese Medicine Macau University of Science and Technology, Av. Wai Long, Macau 999078, China.
Background: Rheumatoid arthritis (RA) is one of the most common forms of arthritis. Extracorporeal shockwave therapy (ESWT) has been identified as a viable alternative therapeutic approach in light of the present protracted clinical course of pharmacological treatment, and changes in levels of marker proteins in the blood samples of RA patients can be utilized to assess treatment outcomes.
Methods: A randomized controlled trial was conducted involving forty patients diagnosed with rheumatoid arthritis (RA) who were assigned randomly to two groups.
PTX-RPPR, a conjugate of paclitaxel and NRP-1 peptide inhibitor to prevent tumor growth and metastasis.
Biomed Pharmacother
September 2024
Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Capital Medical University, Beijing 100069, China; Engineering Research Center of Endogenous Prophylactic of Ministry of Education of China, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Capital Medical University, Beijing 100069, China; Beijing Laboratory of Biomedical Materials and Key Laboratory of Biomedical Materials of Natural Macromolecules, Department of Biomaterials, College of Materials Science and Engineering, Beijing University of Chemical Technology, Beijing 100026, China. Electronic address:
Paclitaxel, a potent anti-tumor drug widely recognized for its therapeutic efficacy, has faced limitations in clinical application due to its poor solubility. The use of Cremophor EL (CrEL) as a cosolvent in paclitaxel injections has been associated with hypersensitivity reactions in some patients. To overcome these challenges, we have developed a novel conjugate by linking a neuropilin-1 targeting peptide, RPPR, to paclitaxel, resulting in PTX-RPPR.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!